chr16-74716461-C-T
Variant summary
Our verdict is Uncertain significance. Variant got 2 ACMG points: 4P and 2B. PM1PM2BP4_Moderate
The NM_024306.5(FA2H):c.925G>A(p.Val309Ile) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000161 in 1,613,938 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 15/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_024306.5 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | UniProt |
---|---|---|---|---|---|---|---|
FA2H | NM_024306.5 | c.925G>A | p.Val309Ile | missense_variant | 6/7 | ENST00000219368.8 | |
FA2H | XM_011523319.3 | c.685G>A | p.Val229Ile | missense_variant | 6/7 | ||
FA2H | XM_011523317.4 | c.*1789G>A | 3_prime_UTR_variant | 6/6 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|
FA2H | ENST00000219368.8 | c.925G>A | p.Val309Ile | missense_variant | 6/7 | 1 | NM_024306.5 | P1 | |
FA2H | ENST00000562145.1 | n.646G>A | non_coding_transcript_exon_variant | 1/2 | 1 | ||||
FA2H | ENST00000567683.5 | c.*204G>A | 3_prime_UTR_variant, NMD_transcript_variant | 4/5 | 2 |
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 151954Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.000211 AC: 53AN: 251198Hom.: 0 AF XY: 0.000199 AC XY: 27AN XY: 135790
GnomAD4 exome AF: 0.000159 AC: 232AN: 1461866Hom.: 0 Cov.: 30 AF XY: 0.000155 AC XY: 113AN XY: 727234
GnomAD4 genome AF: 0.000184 AC: 28AN: 152072Hom.: 0 Cov.: 31 AF XY: 0.000188 AC XY: 14AN XY: 74338
ClinVar
Submissions by phenotype
not provided Uncertain:5
Uncertain significance, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Joint Genome Diagnostic Labs from Nijmegen and Maastricht, Radboudumc and MUMC+ | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | May 01, 2024 | FA2H: PM2, BP4 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | May 17, 2019 | In silico analysis, which includes protein predictors and evolutionary conservation, supports that this variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | May 05, 2022 | BP4 - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Athena Diagnostics | Aug 12, 2016 | - - |
Hereditary spastic paraplegia Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Dec 12, 2016 | - - |
Spastic paraplegia Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 18, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at